Data as of . Holdings from the fund’s latest public SEC N-PORT filing; overlap and active share computed by ETFIQ against the IVV and QQQM books; returns from Tiingo end-of-day prices with distributions reinvested.
GNOM · Global X Genomics & Biotechnology ETF
Global X · Themes desk
Open the live card on ETFIQBy weight, 18% of GNOM's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 43% of the fund across 50 positions, as filed for May 31, 2026. Over the year to Sep 4, 2026 the fund returned +75.7% with distributions reinvested against +20.0% for the S&P 500, so a holder was ahead by 55.8 pts. It sits 41.5% below its all-time high of Feb 8, 2021.
| Theme (ETFIQ, editorial) | Genomics and biotech innovation |
|---|---|
| Launched | Apr 10, 2019 |
| Already in the S&P 500, by weight (ETFIQ) | 17.9% |
| Active share vs the S&P 500 (ETFIQ) | 97.6% |
| Already in the Nasdaq-100, by weight (ETFIQ) | 5.9% |
| Active share vs the Nasdaq-100 (ETFIQ) | 98.8% |
| Top ten holdings weight | 42.6% |
| Holdings | 50 |
| Net assets (latest filing) | $56M |
| Holdings as of (SEC N-PORT) | May 31, 2026 |
| Top holdings | GUARDANT HEALTH, INC. 5.6%, ILLUMINA, INC. 4.8%, NATERA, INC. 4.2%, BIOMARIN PHARMACEUTICAL INC. 4.1%, ARROWHEAD PHARMACEUTICALS, INC. 4.1%, Legend Biotech Corp 4.0%, Praxis Precision Medicines Inc 4.0%, Twist Bioscience Corp 4.0%, VERTEX PHARMACEUTICALS INCORPORATED 4.0%, CRISPR Therapeutics AG 3.9% |
| 3 months: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +32.5% / +4.7% / +27.8 pts / +30.4 pts |
| 6 months: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +42.3% / +15.2% / +27.1 pts / +22.1 pts |
| 1 year: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +75.7% / +20.0% / +55.8 pts / +50.1 pts |
| 3 years: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +46.0% / +78.0% / −31.9 pts / −47.4 pts |
| since launch: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +6.3% / +197.5% / −191.2 pts / −299.5 pts |
| Below its all-time high (ETFIQ) | −41.5% |
| Expense ratio (prospectus XBRL) | 0.50% |
| Fee for the part that differs from the S&P 500, active expense ratio (ETFIQ) | 0.51% |
| Closest funds by holdings overlap | ARKG 37%, HELX 30%, EKG 25%, HTEC 22%, IDNA 20% |
Questions people ask
- How much of GNOM is already in the S&P 500?
- By its holdings filed for May 31, 2026, 18% of GNOM by weight is stocks the S&P 500 already holds. Its active share against the index is 98%, so that share is the part doing something different.
- What does GNOM hold?
- 50 positions as filed for May 31, 2026, with the top ten at 43% of the fund. The largest are GUARDANT HEALTH, INC. at 5.6%, ILLUMINA, INC. at 4.8%, NATERA, INC. at 4.2%.
- Has GNOM beaten the S&P 500?
- Over the year to Sep 4, 2026 GNOM returned +75.7% with distributions reinvested, against +20.0% for the S&P 500, so it finished ahead of the index by 55.8 points.
- What does GNOM cost?
- The prospectus expense ratio is 0.50% a year. Because 98% of the fund differs from the S&P 500, the fee on that differing part works out at 0.51%.
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Funds near this one
Put this on your own page
The difference bar for GNOM, redrawn every trading night. Free to use with the credit link; paste these two lines into any page or newsletter.
<a href="https://etfiq.com/funds/GNOM.html"><img src="https://etfiq.com/embed/themes/GNOM.svg" alt="GNOM difference bar, ETFIQ" width="640"></a>
<p><a href="https://etfiq.com/funds/GNOM.html">GNOM difference bar, updated daily by ETFIQ</a></p>Cite this page. ETFIQ, GNOM on the themes desk, data as of Sep 4, 2026. https://etfiq.com/funds/GNOM.html Free to use with attribution; the underlying files are at Open data.
ETFIQ is an independent publisher of exchange-traded fund data. It is not a fund issuer, broker-dealer or investment adviser, and it makes no recommendations; sort orders and figures are stated arithmetic on published data. Standards · How to read this desk